Dassault Systèmes agreed to buy Arisglobal for up to $2 billion, aiming to consolidate fragmented life-sciences data and strengthen its bid to build a unified AI intelligence platform. The deal combines Arisglobal’s AI-powered safety and regulatory intelligence platform with Dassault’s simulation and modeling capabilities. The acquisition is positioned as a step toward unifying “real-world evidence with virtual evidence,” a key differentiator in how companies simulate and validate regulatory pathways and post-market profiles. Dassault says the combined offering will serve as an industry-wide AI platform for safety and compliance workflows. By bringing together different parts of the biopharma data stack—regulatory intelligence and scientific modeling—Dassault is targeting a broader automation layer across R&D and regulatory execution rather than point solutions. The transaction further illustrates the continuing shift of enterprise software vendors into core biopharma workflow areas where operational data integration is becoming a competitive advantage.